SEC filing record
Primary Source · SEC.gov

TENAX THERAPEUTICS, INC.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2024-08-23Last filing 2024-08-23

Raised

$100M

Investors

24

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

TENAX THERAPEUTICS, INC. is a Delaware corporation that filed a Form D with the SEC on August 23, 2024 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. TENAX THERAPEUTICS, INC. reported $99,681,169 sold from 24 investors of a $174,999,993 total offering as of the Form D filed August 23, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Leerink Partners LLC (CRD 39011), associated with None; Guggenheim Securities, LLC (CRD 40638), associated with None; William Blair & Company, L.L.C. (CRD 1252), associated with None; Roth Capital Partners, LLC (CRD 15407), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $6,830,870 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0000034956
Entity NameTENAX THERAPEUTICS, INC.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517
Phone(919) 855-2100
Former NamesOXYGEN BIOTHERAPEUTICS, INC. (until September 15, 2014); SYNTHETIC BLOOD INTERNATIONAL INC (until June 30, 2008)
Industry / Fund TypePharmaceuticals
Securities TypeEquity
First Sale DateAugust 8, 2024
Filing DateAugust 23, 2024
Accession Number0001578563-24-000391
Total Offering Amount$174,999,993
Total Amount Sold$99,681,169
Amount Remaining$75,318,824
Total Investors24
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$6,830,870 (to Leerink Partners LLC and 3 others)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)NC
Amendment Count5 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Aug 23, 2024

Critical / warning

0 / 0

1 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

closed, lapsed

Latest event New filer · Aug 23, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Beneficially owned by MORGAN STANLEY · full family and the filing behind each link in the terminal

Investor

  • The full fund family and 1 related vehicle (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 1 filing event with values and deltas, latest 2024-08-23, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-08-23: 1 related person added and 3 removed against the filing of 2022-06-01; 8 now listed. The names are in the Terminal feed.

Christopher T. Giordano

Executive Officer, Director · Chapel Hill, NC

President and Chief Executive Officer

Lawrence R. Hoffman

Executive Officer · Chapel Hill, NC

Interim Chief Financial Officer

Michael R. Davidson

Director · Chapel Hill, NC

Declan R. Doogan

Director · Chapel Hill, NC

Gerald T. Proehl

Director · Chapel Hill, NC

Robyn M. Hunter

Director · Chapel Hill, NC

Stuart M. Rich

Executive Officer, Director · Chapel Hill, NC

Chief Medical Officer

June M. Almenoff

Director · Chapel Hill, NC

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Leerink Partners LLCCRD 39011 on BrokerCheck

Associated broker-dealer: None · Boston, MA · Soliciting in all states

Guggenheim Securities, LLCCRD 40638 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

William Blair & Company, L.L.C.CRD 1252 on BrokerCheck

Associated broker-dealer: None · Chicago, IL · Soliciting in all states

Roth Capital Partners, LLCCRD 15407 on BrokerCheck

Associated broker-dealer: None · Newport Beach, CA · Soliciting in all states

Questions About TENAX THERAPEUTICS, INC.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is TENAX THERAPEUTICS, INC.?

TENAX THERAPEUTICS, INC. is a Delaware corporation that filed a Form D with the SEC on August 23, 2024 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.

Is TENAX THERAPEUTICS, INC. legit?

AltStreet does not rate legitimacy; it reports the public record. TENAX THERAPEUTICS, INC. filed a Form D with the SEC on August 23, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $99,681,169 sold to 24 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is TENAX THERAPEUTICS, INC. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that TENAX THERAPEUTICS, INC. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has TENAX THERAPEUTICS, INC. raised?

TENAX THERAPEUTICS, INC. reported $99,681,169 sold from 24 investors of a $174,999,993 total offering as of the Form D filed August 23, 2024.

Who can invest in TENAX THERAPEUTICS, INC.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in TENAX THERAPEUTICS, INC.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling TENAX THERAPEUTICS, INC. and how are they paid?

The Form D names Leerink Partners LLC (CRD 39011), associated with None; Guggenheim Securities, LLC (CRD 40638), associated with None; William Blair & Company, L.L.C. (CRD 1252), associated with None; Roth Capital Partners, LLC (CRD 15407), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $6,830,870 and finders' fees as $0. Form D allows these to be estimates.

Who is behind TENAX THERAPEUTICS, INC.?

The Form D lists 8 related persons: Christopher T. Giordano, executive officer, director (President and Chief Executive Officer); Lawrence R. Hoffman, executive officer (Interim Chief Financial Officer); Michael R. Davidson, director; Declan R. Doogan, director; Gerald T. Proehl, director; Robyn M. Hunter, director; Stuart M. Rich, executive officer, director (Chief Medical Officer); June M. Almenoff, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is TENAX THERAPEUTICS, INC. located?

The issuer's address on its SEC filings is 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517. Its phone number of record is 919-855-2100. It is organized under the laws of Delaware.

How long is the TENAX THERAPEUTICS, INC. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is TENAX THERAPEUTICS, INC.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.